CN115120817A

CN115120817A - Drug delivery device

Info

Publication number: CN115120817A
Application number: CN202210786307.3A
Authority: CN
Inventors: 黄伟聪
Original assignee: Guangdong Flexwarm Advanced Materials & Technology Co ltd
Current assignee: Guangdong Flexwarm Advanced Materials & Technology Co ltd
Priority date: 2022-07-04
Filing date: 2022-07-04
Publication date: 2022-09-30

Abstract

The invention provides a drug delivery device, and relates to the field of atomization drug delivery. The drug delivery device comprises a shell, an atomization assembly, an airflow assembly and an electric control assembly, wherein the atomization assembly, the airflow assembly and the electric control assembly are all arranged on the shell; the atomization assembly is electrically connected with the electric control assembly; the airflow component is electrically connected with the electric control component. The atomization component receives the medicine and then atomizes the medicine under the control of the electric control component. Meanwhile, the airflow component generates airflow under the control of the electric control component, and the atomized medicine is discharged for the inhalation of the patient. In the process, the electric control assembly controls the liquefying speed of the medicine after gasification by controlling the flow rate of the air flow so as to control the granularity of the atomized medicine, so that the granularity of the atomized medicine is matched with the medicine application area, and the medicine is accurately delivered to the part of the human body needing treatment.

Description

Drug delivery device

Technical Field

The invention relates to the field of atomization administration, in particular to an administration device.

Background

The atomized medicine is delivered to the respiratory tract system, and the medicine with different granularities is suitable for different areas of the respiratory tract system. For example, drugs with a particle size greater than 7 μm are suitable for nasal or oral administration, drugs with a particle size between 4.7 μm and 7 μm are suitable for throat administration, and so on.

However, the conventional atomizing administration device cannot control the particle size of the medicine obtained by atomization, and thus cannot accurately deliver the medicine to a site of a human body to be treated.

Disclosure of Invention

In order to solve the problems of the prior art, the present invention aims to provide a drug delivery device.

The invention provides the following technical scheme:

a drug delivery device comprises a shell, an atomization assembly, an airflow assembly and an electric control assembly, wherein the atomization assembly, the airflow assembly and the electric control assembly are all arranged on the shell;

the atomization assembly is electrically connected with the electric control assembly and is used for receiving the medicine and atomizing the medicine;

the airflow component is electrically connected with the electric control component and is used for generating airflow to discharge the atomized medicine;

the electric control assembly controls the liquefying speed of the medicine after gasification by controlling the flow rate of the air flow so as to control the granularity of the medicine after atomization.

As a further alternative to the drug delivery device, the electronic control assembly further controls the degree of agglomeration after the drug is aerosolized by controlling the flow rate of the air flow to control the particle size of the drug after the drug is aerosolized.

As a further alternative to the drug delivery device, the nebulizing assembly comprises an electrically heated nebulizer;

the electric control assembly also controls the saturation degree of the medicine gasification by controlling the heating temperature of the electric heating atomizer so as to control the granularity of the medicine after atomization.

As a further alternative to the drug delivery device, the electronic control assembly comprises an air pressure sensor for monitoring the air pressure of the air flow.

As a further alternative to the drug delivery device, the electronic control assembly comprises a temperature sensor for monitoring the temperature of the medicament after aerosolization.

As a further alternative to the drug delivery device, the drug delivery device further comprises a drug storage assembly and a sealing assembly, the sealing assembly is arranged on the housing, and the sealing assembly is provided with a drug supply channel;

store up the medicine subassembly with atomization component all connects seal assembly, store up the medicine subassembly with atomization component passes through supply the medicine passageway intercommunication.

As a further alternative to the drug delivery device, the seal assembly comprises an elastomeric seal, the supply passage being provided in the elastomeric seal;

store up the medicine subassembly and inlay and locate elastic sealing element, store up the medicine subassembly with elastic sealing element interference fit.

As a further alternative to the drug delivery device, the sealing assembly further comprises a support located below the drug storage assembly, the support abutting the drug storage assembly.

As a further alternative to the drug delivery device, the drug storage assembly comprises a liquid level sensor, which is electrically connected to the electronic control assembly.

As a further alternative to the drug delivery device, the drug storage assembly comprises a communication unit, and the communication unit is wirelessly or electrically connected with the electronic control assembly.

As a further alternative to the drug delivery device, the drug delivery device further comprises a static electricity generating assembly electrically connected with the electronic control assembly;

the electric control assembly also controls the drug to agglomerate and disperse after atomization by controlling the static electricity generating assembly to generate static electricity so as to control the granularity of the drug after atomization.

As a further alternative to the drug delivery device, the static electricity generating component is a negative ion generator.

The embodiment of the invention has the following beneficial effects:

after the atomization component receives the medicine, the medicine is atomized under the control of the electric control component. Meanwhile, the airflow component generates airflow under the control of the electric control component, and the atomized medicine is discharged for the inhalation of the patient. In the process, the electric control assembly controls the liquefying speed of the medicine after gasification by controlling the flow velocity of the air flow so as to control the granularity of the atomized medicine, so that the granularity of the atomized medicine is matched with the medicine application area, and the medicine is accurately delivered to the part of the human body needing treatment.

In order to make the aforementioned and other objects, features and advantages of the present invention more comprehensible and obvious, preferred embodiments accompanied with figures are described in detail below.

Drawings

In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required in the embodiments will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and those skilled in the art can also obtain other related drawings based on the drawings without inventive efforts.

FIG. 1 is a schematic view showing the overall structure of a medication administering device provided in example 1 of the present invention;

fig. 2 is a schematic view showing the overall structure of a drug delivery device provided in example 2 of the present invention;

fig. 3 is a schematic view showing the internal structure of a medication administering device according to example 2 of the present invention;

FIG. 4 is a schematic view showing the connection between the drug storage assembly and the sealing assembly in the drug delivery device according to example 2 of the present invention;

fig. 5 is a schematic view illustrating a connection relationship between a sealing assembly and an atomizing assembly in a drug delivery device provided in embodiment 2 of the present invention.

Description of the main element symbols:

100-a housing; 110-a body; 120-a first bifurcation; 130-a second bifurcation; 140-a discharge channel; 150-inlet holes; 160-gas flow channel; 200-a drug storage assembly; 300-a seal assembly; 310-an elastic sealing member; 311-a drug delivery channel; 320-a support; 400-an atomizing assembly; 410-an atomizing core; 420-a housing; 421-an atomizing cavity; 500-an airflow assembly; 600-an electronic control assembly.

Detailed Description

Reference will now be made in detail to embodiments of the present invention, examples of which are illustrated in the accompanying drawings, wherein like or similar reference numerals refer to the same or similar elements or elements having the same or similar function throughout. The embodiments described below with reference to the accompanying drawings are illustrative only for the purpose of explaining the present invention, and are not to be construed as limiting the present invention.

It will be understood that when an element is referred to as being "secured to" another element, it can be directly on the other element or intervening elements may also be present. When an element is referred to as being "connected" to another element, it can be directly connected to the other element or intervening elements may also be present. In contrast, when an element is referred to as being "directly on" another element, there are no intervening elements present. The terms "vertical," "horizontal," "left," "right," and the like as used herein are for illustrative purposes only.

In the present invention, unless otherwise expressly stated or limited, the terms "mounted," "connected," "secured," and the like are to be construed broadly and can, for example, be fixedly connected, detachably connected, or integrally formed; can be mechanically or electrically connected; either directly or indirectly through intervening media, either internally or in any other relationship. The specific meanings of the above terms in the present invention can be understood by those skilled in the art according to specific situations.

Furthermore, the terms "first", "second" and "first" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or to implicitly indicate the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. In the description of the present invention, "a plurality" means two or more unless specifically defined otherwise.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used in the description of the templates herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.

Example 1

Referring to fig. 1, the present embodiment provides a drug delivery device, which includes a housing 100, an atomizing assembly 400, an airflow assembly 500, and an electronic control assembly 600, wherein the atomizing assembly 400, the airflow assembly 500, and the electronic control assembly 600 are disposed in the housing 100.

Specifically, the atomizing assembly 400 is used for receiving the medicine, and both the atomizing assembly 400 and the airflow assembly 500 are electrically connected to the electronic control assembly 600. Under the control of the electric control assembly 600, the atomizing assembly 400 atomizes the medicine, and the airflow assembly 500 can generate an airflow and discharge the atomized medicine by using the airflow for the patient to inhale.

In the above process, the electric control assembly 600 controls the liquefaction speed of the medicine after gasification by controlling the flow rate of the air flow, so as to control the granularity of the atomized medicine, and the granularity of the atomized medicine is matched with the medicine application area, so that the medicine is accurately delivered to the part of the human body to be treated.

Example 2

Referring to fig. 2, the present embodiment provides a drug delivery device, which comprises a housing 100, a drug storage assembly 200, a sealing assembly 300, an atomizing assembly 400, an airflow assembly 500, an electric control assembly 600, and an electrostatic generating assembly. The medicine storage assembly 200, the sealing assembly 300, the atomizing assembly 400, the airflow assembly 500, the electric control assembly 600 and the static electricity generating assembly are all directly or indirectly arranged in the housing 100, and the atomizing assembly 400, the airflow assembly 500 and the static electricity generating assembly are all electrically connected with the electric control assembly 600.

Wherein, the medicine storage assembly 200 stores the medicine and supplies the medicine stored therein to the atomizing assembly 400. The seal assembly 300 functions to seal during the drug delivery process. After the medicament is supplied to the atomizing assembly 400, the atomizing assembly 400 atomizes the medicament under the control of the electric control assembly 600. On the basis, the electronic control assembly 600 controls the airflow assembly 500 to generate airflow, and the atomized medicine is discharged by using the airflow.

In the process, the electric control assembly 600 controls the liquefying speed of the medicine after gasification by controlling the flow rate of the air flow, controls the agglomeration degree of the medicine after atomization by controlling the flow rate of the air flow, and controls the agglomeration and dispersion of the medicine after atomization by controlling the static electricity generation assembly to generate static electricity, thereby controlling the granularity of the medicine after atomization.

Referring to fig. 3, in particular, the housing 100 is composed of a main body 110, a first branch part 120 and a second branch part 130, and the first branch part 120 and the second branch part 130 are located at one end of the main body 110.

Main body 110 is held by the patient, and airflow assembly 500 and electronic control assembly 600 are both disposed within main body 110. The drug storage assembly 200, the sealing assembly 300 and the aerosolizing assembly 400 are disposed within the first prong 120, and the discharge channel 140 is disposed within the second prong 130.

In addition, an air inlet 150 is opened on the side wall of the housing 100, and an air flow channel 160 is provided in the housing 100. The intake vents 150 communicate with the airflow channel 160 through the airflow assembly 500, and the airflow channel 160 communicates with the exhaust channel 140 through the atomizing assembly 400.

In use, ambient air enters the interior of the housing 100 through the air inlet 150, flows along the air flow channel 160 to the atomizing assembly 400 under the driving of the air flow assembly 500, and then entrains the atomized medicine and is discharged from the discharge channel 140 for inhalation by a patient.

Referring to fig. 4 and 5, in particular, the sealing assembly 300 and the atomizing assembly 400 are packaged together, and the sealing assembly 300 and the atomizing assembly 400 are directly fixed in the housing 100. The drug storage assembly 200 is detachably connected to the sealing assembly 300, and thus is integrally formed with the atomizing assembly 400 and is indirectly fixed in the housing 100.

In addition, the sealing assembly 300 is provided with a medicine supply channel 311, and the medicine storage assembly 200 is communicated with the atomizing assembly 400 through the medicine supply channel 311.

Specifically, the drug storage assembly 200 is comprised of a drug storage bottle, a level sensor and a communication unit.

The drug storage bottle has a mouth portion with an opening, the mouth portion is embedded and fixed in the sealing component 300, and the mouth portion is communicated with the drug supply channel 311.

Level sensor sets up in the medicine storage bottle, and level sensor is connected with automatically controlled subassembly 600 electricity, and level sensor monitors the liquid level in the medicine storage bottle and feeds back to automatically controlled subassembly 600.

When the atomizing assembly 400 atomizes the medicine, the medicine in the medicine storage bottle is continuously supplied to the atomizing assembly 400 through the medicine supply channel 311, and the liquid level in the medicine storage bottle is gradually lowered. The electronic control unit 600 calculates the amount of the medicine supplied from the medicine storage unit 200 to the atomizing unit 400 according to the variation of the liquid level in the medicine storage bottle, and controls the atomizing unit 400 to be turned off when the amount reaches a preset value.

The communication unit is arranged on the medicine storage bottle and is wirelessly connected with the electric control assembly 600. The communication unit can transmit information (such as dosage and particle size) of the medicine in the medicine storage assembly 200 to the electronic control assembly 600, and the electronic control assembly 600 controls the atomizing assembly 400 and the airflow assembly 500 according to the information of the medicine.

In this embodiment, the communication unit adopts an NFC tag, which has an NFC data transmission function, and the electronic control component 600 has an NFC reading function.

In another embodiment of the present application, the communication unit may also be electrically connected to the electronic control unit 600 through the contact, so as to transmit the information of the medicine in the medicine storage unit 200 to the electronic control unit 600.

Specifically, the seal assembly 300 is comprised of a resilient seal 310 and a support 320.

The medicine supply passage 311 is opened in the elastic sealing member 310, the mouth portion is also fitted in the elastic sealing member 310, and the mouth portion is fixed by frictional force by interference fit with the elastic sealing member 310. In addition, the outside wall of the finish portion is provided with a pit to enhance the connection between the finish portion and the elastomeric seal 310.

The support member 320 is connected to the resilient seal member 310, and the support member 320 is disposed below the drug storage assembly 200 in abutment with the drug storage assembly 200.

When the main body 110 is held by the patient in the upright position, the medicine storage assembly 200, the sealing assembly 300 and the atomizing assembly 400 located in the first diverging part 120 are all in the tilted position. The provision of the support member 320 to support the drug storage assembly 200 enables a more stable connection between the drug storage assembly 200 and the resilient seal 310.

In the present embodiment, the elastic sealing member 310 and the supporting member 320 are made of silicone and are integrally formed.

Specifically, the atomizing assembly 400 is comprised of an atomizing core 410 and a housing 420.

The atomizing core 410 is embedded in the elastic sealing member 310 and communicates with the medicine feed passage 311. The medicine in the medicine supply channel 311 can penetrate into the atomizing core 410 and be atomized by the atomizing core 410, and the medicine in the medicine storage bottle is continuously supplemented into the medicine supply channel 311. In addition, the atomizing core 410 is electrically connected to the electronic control assembly 600.

The housing 420 surrounds the elastic sealing member 310 and is fixedly connected to the elastic sealing member 310. An atomizing chamber 421 is formed inside the housing 420, one end of the atomizing chamber 421 is communicated with the airflow channel 160, one end of the atomizing chamber 421 is communicated with the discharge channel 140, and the atomizing core 410 is exposed in the atomizing chamber 421.

Further, in the present embodiment, the atomizing core 410 is an electrically heated atomizer, and the heating element thereof may be a printed heating circuit, a sintered heating circuit, a co-fired heating circuit, or cotton embedded with a heating wire. The atomizing core 410 heats the medicine to vaporize the medicine. The gasified medicine is liquefied again to form mist-shaped liquid drops.

Correspondingly, the electric control assembly 600 also controls the saturation degree of the medicine gasification by controlling the heating temperature of the electric heating atomizer, so as to control the granularity of the medicine after atomization.

In another embodiment of the present application, the atomizing core 410 may also be an ultrasonic atomizer.

Further, the atomizing core 410 is electrically connected to the electronic control assembly 600 through metal contacts and metal contacts.

Wherein, the metal contact is packaged with the atomizing assembly 400, and the metal contact is always electrically connected with the atomizing core 410. Metal contacts are provided on the housing 100, and the metal contacts are electrically connected to the electronic control assembly 600 at all times.

Referring again to fig. 3, specifically, the airflow assembly 500 is composed of a fan and a micro motor.

The fan is connected with the output end of the micro motor, and the micro motor is electrically connected with the electric control assembly 600. After the electric control assembly 600 controls the micro motor to be turned on, the micro motor can drive the fan to rotate, and further, air flow is generated. The electric control assembly 600 controls the rotation speed of the micro motor, i.e. the rotation speed of the fan can be controlled, and further the flow rate of the air flow can be controlled.

The airflow generated by airflow assembly 500 enters nebulization chamber 421 via airflow channel 160, mixes with the drug and exchanges heat with the drug. When the flow rate of the gas flow is faster, the heat exchange between the gas flow and the gasified medicine is more intense, and the speed of liquefaction of the medicine is faster.

Specifically, the electronic control assembly 600 is composed of a power supply, a controller, an air pressure sensor, and a temperature sensor.

Wherein the power supply provides power to the controller, atomizing core 410 and other electronic components such as a micro-motor.

The controller is simultaneously electrically connected with the liquid level sensor, the atomizing core 410, the micro motor, the air pressure sensor and the temperature sensor and is wirelessly connected with the communication unit.

The air pressure sensor is used for monitoring the air pressure of the air flow, and the temperature sensor is used for monitoring the temperature of the atomized medicine.

On one hand, the controller controls the micro motor according to information fed back by the air pressure sensor and the temperature sensor, and further controls the flow rate of the air flow. On the other hand, the controller controls the power of the atomizing core 410 according to the information fed back by the temperature sensor, and further controls the atomizing temperature. In addition, the controller also controls time according to the atomization temperature and the type of the medicine, so as to confirm the dosage.

Specifically, the static electricity generating assembly employs a negative ion generator.

In short, in the above drug delivery device, the electronic control assembly 600 controls the flow rate of the air flow, which can control the liquefaction speed of the drug after gasification, and also can control the agglomeration degree of the drug after atomization, and finally realize the control of the particle size of the drug after atomization. Therefore, the granularity of the atomized medicine is matched with the medicine application area, so that the medicine can be accurately delivered to the part of the human body needing to be treated.

In all examples shown and described herein, any particular value should be construed as merely exemplary, and not as a limitation, and thus other examples of example embodiments may have different values.

It should be noted that: like reference numbers and letters refer to like items in the following figures, and thus, once an item is defined in one figure, it need not be further defined and explained in subsequent figures.

The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is specific and detailed, but not to be construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention.

Claims

1. The drug delivery device is characterized by comprising a shell, an atomization assembly, an airflow assembly and an electric control assembly, wherein the atomization assembly, the airflow assembly and the electric control assembly are all arranged on the shell;

the electric control assembly controls the speed of the medicine after being gasified to be liquefied by controlling the flow rate of the air flow so as to control the granularity of the medicine after being atomized.

2. The drug delivery device of claim 1, wherein the electrical control assembly further controls the degree of agglomeration of the aerosolized drug by controlling the flow rate of the airflow to control the particle size of the aerosolized drug.

3. The drug delivery device of claim 1, wherein the nebulizing assembly comprises an electrically heated nebulizer;

4. The medication delivery device of claim 1, wherein the electrical control assembly comprises a gas pressure sensor for monitoring the gas pressure of the gas flow.

5. The drug delivery device of claim 1, wherein the electrical control assembly comprises a temperature sensor for monitoring the temperature of the drug after aerosolization.

6. The drug delivery device according to any of claims 1 to 5, further comprising a drug storage assembly and a sealing assembly, the sealing assembly being provided to the housing, the sealing assembly being provided with a drug supply channel;

7. The drug delivery device of claim 6, wherein the seal assembly comprises an elastomeric seal, the drug delivery channel being provided in the elastomeric seal;

8. The drug delivery device of claim 7, wherein the seal assembly further comprises a support located below the drug storage assembly, the support abutting the drug storage assembly.

9. The drug delivery device of claim 6, wherein the drug storage assembly comprises a level sensor electrically connected to the electronic control assembly.

10. The medication delivery device of claim 6, wherein the medication storage assembly comprises a communication unit that is wirelessly or electrically connected to the electronic control assembly.

11. The drug delivery device of claim 1, further comprising an electrostatic generating assembly electrically connected to the electrical control assembly;

12. The drug delivery device of claim 11, wherein the static electricity generating component is a negative ion generator.